Access and Optimism: IRA Reforms and the Road Ahead in PCa Care

7 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
At the American Urological Association 2025 Annual Meeting, an expert panel convened to discuss the latest research and clinical advancements in metastatic hormone-sensitive prostate cancer (mHSPC) diagnostics and treatment. Moderated by Murilo De Almeida Luz, MD, Icahn School of Medicine at Mount Sinai, the roundtable consisted of Gordon Brown, DO, Summit Health; Daniel Oberlin, MD, Golden Gate Urology; and Gregory C. McMahon, DO, MidLantic Urology.

In the final segment of the discussion, the panel concludes with a discussion on how recent Medicare Part D reforms have improved access to advanced prostate cancer treatments by capping out-of-pocket costs, followed by each expert offering optimistic final reflections on the future of care.
Category
Oncology
Be the first to comment

Up Next